Cobra Biologics has been recognized by the French Ministry of Higher Education and Research (MESR) as an approved service provider for its antibody and recombinant protein services for the period 2013 to 2015. The approval allows French companies that outsource their R&D programs to Cobra’s centre of excellence, to receive a research tax credit.
The tax credit, which covers 30% of all R&D expenses up to €100 million, and 5% above this threshold, aims to encourage R&D efforts and enhance investments in France.
Peter Coleman, chief executive officer of Cobra Biologics, said, “CIR is a real benefit to our French customers as it encourages them to invest in innovative drugs that are ultimately the driving force for the medicines of tomorrow.”
Cobra Biologics Gains Approval for R&D Tax Credit
Published April 1, 2014
Related Breaking News
Related Online Exclusives